Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

These headaches are typically a result of how the drug interacts with your body, not a direct effect of the medication.